2024-10-30 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

This report provides an analysis of Johnson & Johnson (JNJ) stock based on the provided data.

**1. Performance vs. S&P 500 (VOO)**

* **Company:** Johnson & Johnson, a multinational pharmaceutical, medical devices, and consumer packaged goods company.
* **Cumulative Return:** 33.61%
* **S&P 500 (VOO) Cumulative Return:** 136.74%
* **Performance Gap:** -103.13% (Relative Performance: 2.22%)
* **Interpretation:** JNJ has significantly underperformed the S&P 500 over the period considered.  It's currently at the 2.22% percentile in terms of relative performance compared to its historical performance against the S&P 500.

**2. Recent Price Movement:**

* **Closing Price:** $160.09 (Last-Market: $160.17)
* **5-Day Moving Average:** $162.42
* **20-Day Moving Average:** $162.09
* **60-Day Moving Average:** $162.67
* **Interpretation:** JNJ is trading below its 5-day, 20-day, and 60-day moving averages, indicating potential downward momentum.

**3. Technical Indicators:**

* **RSI:** 48.38 (Neutral)
* **PPO:** -0.14 (Weak)
* **Delta_Previous_Relative_Divergence:** -5.73 (Short-term Downward Trend)
* **Expected Return:** 0.0% (Long-term, 2+ years, relative to S&P 500)
* **Interpretation:** The technical indicators suggest neutral to weak momentum, with a short-term downward trend. The expected return of 0.0% indicates that JNJ is not anticipated to significantly outperform the S&P 500 in the long-term.

**4. Recent Earnings and Outlook:**

* **Earnings:**
    | Date         | EPS   | Revenue      |
    |--------------|-------|--------------|
    | 2024-10-23 | 1.12  | $22.47 B$   |
    | 2024-07-25 | 1.95  | $22.45 B$   |
    | 2024-05-01 | 1.35  | $21.38 B$   |
    | 2024-02-16 | 1.68  | $21.39 B$   |
    | 2023-10-27 | 10.32 | $21.35 B$   |
* **Interpretation:** The most recent earnings report (2024-10-23) is not provided with an estimated value for comparison.  However, earnings have been relatively stable over the past few quarters, with slight fluctuations.

**5. Financial Information:**

* **Revenue and Profitability:**
    | Quarter      | Revenue      | Profit Margin |
    |--------------|--------------|---------------|
    | 2024-09-30 | $22.47B     | 69.01%       |
    | 2024-06-30 | $22.45B     | 69.40%       |
    | 2024-03-31 | $21.38B     | 69.55%       |
    | 2023-12-31 | $21.39B     | 68.23%       |
    | 2023-09-30 | $21.35B     | 69.06%       |
* **Capital and Profitability:**
    | Quarter      | Equity     | ROE        |
    |--------------|------------|-------------|
    | 2024-09-30 | $70.16B    | 3.84%      |
    | 2024-06-30 | $71.54B    | 6.55%      |
    | 2024-03-31 | $70.02B    | 4.65%      |
    | 2023-12-31 | $68.77B    | 5.89%      |
    | 2023-09-30 | $71.23B    | 36.54%     |
* **Interpretation:** JNJ demonstrates strong profitability with consistent high profit margins, but its Return on Equity (ROE) has been fluctuating. This could indicate potential challenges in capital efficiency and a need for further analysis.

**6. News and Recent Issues:**

* **Recent Earnings News:** No recent earnings news was found within the last 2 days from sources like Shacknews.
* **Recent Market Outlook:** According to FINBOLD, JNJ is generally seen as a safe and stable investment due to its diversified business model and consistent cash flow generation. However, some analysts express concerns about the company's long-term growth potential, given the competitive landscape and potential regulatory hurdles in the pharmaceutical industry. 
* **Analyst Opinions and Performance Highlights:** JNJ is currently rated as a "Hold" by most analysts, with mixed opinions on its future performance. Key highlights include strong dividend yields, a solid track record of consistent revenue generation, and a conservative balance sheet.

**7. Overall Analysis:**

JNJ exhibits mixed signals based on the provided information. While its financial fundamentals remain strong, its recent performance has been underwhelming, particularly compared to the S&P 500. The stock is currently trading below its moving averages and technical indicators point to neutral to weak momentum. While analysts generally view it as a safe investment, concerns about future growth potential exist. 

**Recommendation:** 

Given the current performance and outlook, investors might want to consider holding their existing positions or waiting for further signals before initiating a new position in JNJ. Further research and analysis into the company's specific business lines and future strategic plans are crucial before making any investment decisions. 
